Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pulmonary Therapy
Published in: Pulmonary Therapy 1/2017

Open Access 01-06-2017 | Review

The Respimat® Development Story: Patient-Centered Innovation

Authors: Herbert Wachtel, Sabine Kattenbeck, Stephen Dunne, Bernd Disse

Published in: Pulmonary Therapy | Issue 1/2017

Login to get access

Abstract

The Respimat® Soft Mist™ Inhaler represents a unique delivery system for respiratory medications, using an innovative concept with major technological advancements made during prototype development. The Respimat® concept was driven by the intent to solve problems associated with existing inhaler devices for patient use. The following core aims were achieved: (1) avoiding propellants while reducing requirements for patient coordination and inspiratory effort; (2) optimizing drug delivery to the lungs, and; (3) improving the patients’ experience of taking their inhaled medication. The Respimat® inhaler is the first-marketed, pocket-sized inhaler to successfully generate a metered dose of therapeutic aerosol mist from an aqueous solution. Patient feedback has strongly influenced the evolution of the Respimat® inhaler design and instructions for use. The availability of Respimat® augments options for clinicians and patients seeking to choose an inhaler that can effectively and consistently deliver respiratory medication to targeted areas of the lung. In many countries worldwide, Respimat® is available for the administration of tiotropium, olodaterol (and tiotropium/olodaterol in fixed-dose combination), ipratropium/fenoterol, and ipratropium/albuterol.
Funding: Boehringer Ingelheim.
Literature
1.
Ari A, Fink JB. Guidelines for aerosol devices in infants, children and adults: which to choose, why and how to achieve effective aerosol therapy. Expert Rev Respir Med. 2011;5(4):561–72.CrossRefPubMed
2.
Islam N, Cleary MJ. Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery—a review for multidisciplinary researchers. Med Eng Phys. 2012;34(4):409–27.CrossRefPubMed
3.
4.
Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm. 2004;283(1–2):1–9.CrossRefPubMed
5.
Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft Mist Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl). 2011;4:145–55.PubMedPubMedCentral
6.
Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335–71.CrossRefPubMed
7.
8.
Freedman T. Medihaler therapy for bronchial asthma; a new type of aerosol therapy. Postgrad Med. 1956;20(6):667–73.CrossRefPubMed
9.
Mercer TT. Production of therapeutic aerosols; principles and techniques. Chest. 1981;80(6 Suppl):813–8.PubMed
10.
11.
Bell JH, Hartley PS, Cox JS. Dry powder aerosols. I. A new powder inhalation device. J Pharm Sci. 1971;60(10):1559–64.CrossRefPubMed
12.
Morén F. Drug deposition of pressurised inhalation aerosols. I. Influence of actuator tube design. Int J Pharm. 1978;1:205–12.CrossRef
13.
Newman SP, Moren F, Pavia D, Little F, Clarke SW. Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis. 1981;124(3):317–20.PubMed
14.
Leach CL. Approaches and challenges to use freon propellant replacements. Aerosol Sci Technol. 1995;22(4):328–34.CrossRef
15.
16.
Berodual Respimat (summary of product characteristics) (2004). Boehringer Ingelheim Limited; 2004.
17.
18.
Lavorini F, Fontana GA, Usmani OS. New inhaler devices-the good, the bad and the ugly. Respiration. 2014;88(1):3–15.CrossRefPubMed
19.
Hochrainer D, Holz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18(3):273–82.CrossRefPubMed
20.
Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax. 1991;46(10):712–6.CrossRefPubMedPubMedCentral
21.
Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care. 2005;50(10):1360–74.PubMed
22.
Ganderton D. Targeted delivery of inhaled drugs: current challenges and future goals. J Aerosol Med. 1999;12(Suppl 1):S3–8.PubMed
23.
Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015;8:131–9.PubMedPubMedCentral
24.
Heijerman H, Westerman E, Conway S, Touw D, Doring G. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2009;8(5):295–315.CrossRefPubMed
25.
26.
Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;12(Suppl 1):S19–24.PubMed
27.
Spiriva (tiotropium) Respimat 2.5 micrograms, solution for inhalation (summary of product characteristics) (2016). Boehringer Ingelheim Limited; 2016.
28.
29.
Capstick TG, Clifton IJ. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev Respir Med. 2012;6(1):91–101.CrossRefPubMed
30.
Nichols SC, Mitchell JP, Sandell D, et al. A Multi-laboratory in vitro study to compare data from abbreviated and pharmacopeial impactor measurements for orally inhaled products: a report of the European Aerosol Group (EPAG). AAPS PharmSciTech. 2016;17(6):1383–92.CrossRefPubMed
31.
Wachtel H, Moser A. The Respimat®, a new Soft MistTM inhaler for Delivering Drugs to the Lungs. In: Rathbone MJ, Hadgraft J, Roberts MS, Lane ME, editors. Modified release drug delivery technology. 2nd ed. London: Taylor & Francis; 2008. p. 637–45.CrossRef
32.
Lippmann M. Deposition and clearance of inhaled particles in the human nose. Ann Otol Rhinol Laryngol. 1970;79(3):519–28.CrossRefPubMed
33.
Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest. 1998;113(4):957–63.CrossRefPubMed
34.
Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med. 2005;18(3):264–72.CrossRefPubMed
35.
Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3(4):763–70.PubMedPubMedCentral
36.
Kilfeather SA, Ponitz HH, Beck E, et al. Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD. Respir Med. 2004;98(5):387–97.CrossRefPubMed
37.
von Berg A, Jeena PM, Soemantri PA, et al. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma. Pediatr Pulmonol. 2004;37(3):264–72.CrossRef
38.
Hohlfeld JM, Sharma A, van Noord JA, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54(4):405–14.CrossRefPubMed
39.
Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–501.CrossRefPubMed
40.
Calverley PM, Konen-Bergmann M, Richard F, Bell S, Hohlfeld JM. Tiotropium Respimat versus HandiHaler: comparison of bronchodilator efficacy of various doses in clinical trials. Adv Ther. 2016;33(5):786–93.CrossRefPubMedPubMedCentral
41.
Kattenbeck S (2016) Human factor studies. Case study instructions for use for Respimat®. Presented at: IPAC-RS symposium 2016 at RDD 2016: Meeting the quality challenge for orally inhaled drug products, Scottsdale, Arizona, 21 April 2016.
42.
SPIRIVA Respimat Using your SPIRIVA Respimat inhaler (2015). Boehringer Ingelheim Ltd.
43.
Kamin W, Frank M, Kattenbeck S, Moroni-Zentgraf P, Wachtel H, Zielen S. A handling study to assess use of the Respimat® Soft Mist™ inhaler in children under 5 years old. J Aerosol Med Pulm Drug Deliv. 2015;28(5):372–81.CrossRefPubMedPubMedCentral
44.
Bickmann D, Kamin W, Sharma A, Wachtel H, Moroni-Zentgraf P, Zielen S. In vitro determination of Respimat dose delivery in children: an evaluation based on inhalation flow profiles and mouth–throat models. J Aerosol Med Pulm Drug Deliv. 2015;29(1):76–85.
45.
Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler. Int J Chron Obstruct Pulmon Dis. 2009;4:381–90.CrossRefPubMedPubMedCentral
46.
Braido F, Chrystyn H, Baiardini I, et al. “Trying, But Failing”—the role of inhaler technique and mode of delivery in respiratory medication adherence. J Allergy Clin Immunol Pract. 2016;4(5):823–32.CrossRefPubMed
47.
Rogueda P, Traini D. The future of inhalers: how can we improve drug delivery in asthma and COPD? Expert Rev Respir Med. 2016;10(10):1041–4.CrossRefPubMed
48.
Asakura Y, Nishimura N, Maezawa K, Terajima T, Kizu J, Chohnabayashi N. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. J Aerosol Med Pulm Drug Deliv. 2013;26(1):41–5.CrossRefPubMed
49.
50.
Dal Negro RW, Povero M. Acceptability and preference of three inhalation devices assessed by the Handling Questionnaire in asthma and COPD patients. Multidiscip Respir Med. 2015;11:7.CrossRef
51.
Miravitlles M, Montero-Caballero J, Richard F, et al. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:407–15.CrossRefPubMedPubMedCentral
52.
Schurmann W, Schmidtmann S, Moroni P, Massey D, Qidan M. Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction. Treat Respir Med. 2005;4(1):53–61.CrossRefPubMed
53.
Dal Negro RW, Povero M. The economic impact of educational training assessed by the Handling Questionnaire with three inhalation devices in asthma and Chronic Obstructive Pulmonary Disease patients. Clinicoecon Outcomes Res. 2016;8:171–6.
54.
Dekhuijzen PN, Lavorini F, Usmani OS. Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®). Patient Prefer Adherence. 2016;10:1561–72.CrossRefPubMedPubMedCentral
55.
Kamin W, Krackhardt D, Goessl R, et al. A handling study to assess the use of the Respimat® Soft Mist™ Inhaler in children aged 4–12 years. Pulm Ther. 2015;1:53–63.CrossRef
56.
57.
SPIRIVA® RESPIMAT® (tiotropium bromide) inhalation spray foi Ridgefield, CT, USA: Boehringer Ingelheim Pharmaceuticals, Inc.; 2016.
58.
Moroni-Zentgraf P. Impact of patient needs on design and usage of an inhalation device in respiratory medicine. Respir Drug Deliv Eur. 2013;1:141–52.
Metadata
Title
The Respimat® Development Story: Patient-Centered Innovation
Authors
Herbert Wachtel
Sabine Kattenbeck
Stephen Dunne
Bernd Disse
Publication date
01-06-2017
Publisher
Springer Healthcare
Published in
Pulmonary Therapy / Issue 1/2017
Print ISSN: 2364-1754
Electronic ISSN: 2364-1746
DOI
https://doi.org/10.1007/s41030-017-0040-8

Other articles of this Issue 1/2017

Pulmonary Therapy 1/2017 Go to the issue

Original Research

Validation of a New Portable Exhaled Nitric Oxide Analyzer, NIOX VERO®: Randomized Studies in Asthma

Review

A Review on the Safety and Efficacy of Inhaled Corticosteroids in the Management of Asthma

Original Research

Impact of Inhalation Flow, Inhalation Volume and Critical Handling Errors on Delivered Budesonide/Formoterol Dose in Different Inhalers: An In Vitro Study

Original Research

Aerosol Deposition of Inhaled Corticosteroids/Long-Acting β2-Agonists in the Peripheral Airways of Patients with Asthma Using Functional Respiratory Imaging, a Novel Imaging Technology

Original Research

A Real-World Study of 30-Day Exacerbation Outcomes in Chronic Obstructive Pulmonary Disease (COPD) Patients Managed with Aerobika OPEP

Original Research

Successful Fractional Exhaled Nitric Oxide Measurements with NIOX VERO using 6- and 10-s Exhalation Modes in Children with Asthma Aged 4–10 Years: A Randomized Study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits